Rocket Pharmaceuticals receives FDA approval for rare disease gene therapy

March 27, 2026 7:01 AM

Rocket Pharmaceuticals Inc. (NASDAQ: RCKT) announced that the U.S. Food and Drug Administration has granted accelerated approval for KRESLADI, a ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found